Key facts
- This page summarizes Thilo Schroeder's Form 4 filing for Revolution Medicines, Inc. (RVMD).
- 10 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 04 Mar 2022, 18:22.
Thilo Schroeder - 18 Feb 2020 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)
- Reporting relationship
- Director
- Issuer ticker
- RVMD
- Reported as of
- 18 Feb 2020
- Net transaction value
- +$28,615,233
- SEC form
- 4
- Accepted by SEC
- 04 Mar 2022, 18:22:41 UTC
- Prior SEC filing
- 04 Mar 2022
- Next SEC filing
- 07 May 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Darren DeStefano, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Thilo Schroeder filed Form 4 for Revolution Medicines, Inc. (RVMD) on 04 Mar 2022.
Change
- Previous filing in this sequence was filed on 04 Mar 2022.
- Current net transaction value: +$28,615,233.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RVMD
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +2,118,214
- Change %
- Price
- Shares after
- 2,118,214
- Date
- 18 Feb 2020
- Ownership
- By Nextech V Oncology S.C.S., SICAV-SIF
- Footnotes
- F1, F2
RVMD
transaction
Common Stock
Purchase
- Transaction value
- $6,800,000
- Shares
- +400,000
- Change %
- +19%
- Price
- $17.00
- Shares after
- 2,518,214
- Date
- 18 Feb 2020
- Ownership
- By Nextech V Oncology S.C.S., SICAV-SIF
- Footnotes
- F2
RVMD
transaction
Common Stock
Purchase
- Transaction value
- $3,900,000
- Shares
- +150,000
- Change %
- +6%
- Price
- $26.00
- Shares after
- 2,668,214
- Date
- 13 Jul 2020
- Ownership
- By Nextech V Oncology S.C.S., SICAV-SIF
- Footnotes
- F2
RVMD
transaction
Common Stock
Purchase
- Transaction value
- $13,500,000
- Shares
- +300,000
- Change %
- Price
- $45.00
- Shares after
- 300,000
- Date
- 08 Feb 2021
- Ownership
- By Nextech VI Oncology SCSp
- Footnotes
- F3
RVMD
transaction
Common Stock
Purchase
- Transaction value
- $2,202,533
- Shares
- +116,290
- Change %
- Price
- $18.94
- Shares after
- 116,290
- Date
- 02 Mar 2022
- Ownership
- By Nextech Crossover I SCSP
- Footnotes
- F4, F5
RVMD
transaction
Common Stock
Purchase
- Transaction value
- $1,008,753
- Shares
- +54,764
- Change %
- +47%
- Price
- $18.42
- Shares after
- 171,054
- Date
- 03 Mar 2022
- Ownership
- By Nextech Crossover I SCSP
- Footnotes
- F5, F6
RVMD
transaction
Common Stock
Purchase
- Transaction value
- $208,000
- Shares
- +10,873
- Change %
- +6.4%
- Price
- $19.13
- Shares after
- 181,927
- Date
- 03 Mar 2022
- Ownership
- By Nextech Crossover I SCSP
- Footnotes
- F5, F7
RVMD
transaction
Common Stock
Purchase
- Transaction value
- $995,947
- Shares
- +56,300
- Change %
- +31%
- Price
- $17.69
- Shares after
- 238,227
- Date
- 04 Mar 2022
- Ownership
- By Nextech Crossover I SCSP
- Footnotes
- F5, F8
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RVMD
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -1,569,539
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 18 Feb 2020
- Ownership
- By Nextech V Oncology S.C.S., SICAV-SIF
- Underlying class
- Common Stock
- Underlying amount
- 1,569,539
- Exercise price
- Footnotes
- F1, F2
RVMD
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -548,675
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 18 Feb 2020
- Ownership
- By Nextech V Oncology S.C.S., SICAV-SIF
- Underlying class
- Common Stock
- Underlying amount
- 548,675
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 8 footnotes
Footnote F1
Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering.
Footnote F2
Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Footnote F3
Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.62 to $19.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Footnote F5
Nextech Invest AG is the investment advisor of Nextech Crossover I SCSP ("Nextech Crossover"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech Crossover. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Footnote F6
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.03 to $18.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Footnote F7
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.05 to $19.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Footnote F8
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.25 to $18.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.